GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sight Sciences Inc (NAS:SGHT) » Definitions » Pretax Margin %

Sight Sciences (Sight Sciences) Pretax Margin % : -84.34% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sight Sciences Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Sight Sciences's Pre-Tax Income for the three months ended in Mar. 2024 was $-16.25 Mil. Sight Sciences's Revenue for the three months ended in Mar. 2024 was $19.27 Mil. Therefore, Sight Sciences's pretax margin for the quarter that ended in Mar. 2024 was -84.34%.

The historical rank and industry rank for Sight Sciences's Pretax Margin % or its related term are showing as below:

SGHT' s Pretax Margin % Range Over the Past 10 Years
Min: -189.85   Med: -123.07   Max: -67.04
Current: -67.04


SGHT's Pretax Margin % is ranked worse than
72.18% of 816 companies
in the Medical Devices & Instruments industry
Industry Median: -0.745 vs SGHT: -67.04

Sight Sciences Pretax Margin % Historical Data

The historical data trend for Sight Sciences's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sight Sciences Pretax Margin % Chart

Sight Sciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial -110.76 -125.30 -128.22 -120.84 -68.39

Sight Sciences Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -90.59 -62.83 -64.76 -56.96 -84.34

Competitive Comparison of Sight Sciences's Pretax Margin %

For the Medical Devices subindustry, Sight Sciences's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sight Sciences's Pretax Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Sight Sciences's Pretax Margin % falls into.



Sight Sciences Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Sight Sciences's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-55.437/81.056
=-68.39 %

Sight Sciences's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-16.249/19.265
=-84.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sight Sciences  (NAS:SGHT) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Sight Sciences Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Sight Sciences's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sight Sciences (Sight Sciences) Business Description

Traded in Other Exchanges
N/A
Address
4040 Campbell Avenue, Suite 100, Menlo Park, CA, USA, 94025
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
Executives
Jeremy B. Hayden officer: Chief Legal Officer 2 MUSICK, 2 MUSICK, IRVINE CA 92618
Sam Boong Park officer: Chief Operating Officer C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Paul Badawi director, 10 percent owner, officer: President and CEO C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
David Badawi director, officer: Chief Technology Officer C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
D1 Capital Partners L.p. 10 percent owner 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
Staffan Encrantz director C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Matthew Link officer: Chief Commercial Officer 7475 LUSK BLVD, SAN DIEGO CA 92121
Catherine Mazzacco director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Alison Bauerlein officer: See remarks 326 BOLLAY DRIVE, GOLETA CA 93117
James Rodberg officer: See Remarks C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVE., SUITE 100, MENLO PARK CA 94025
Tamara Fountain director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Brenda Jane Larsen-becker director C/O SIGHT SCIENCES, INC., 3000 SAND HILL ROAD, BUILDING 3, STE 105, MENLO PARK CA 94025
Jesse Selnick officer: Chief Financial Officer C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Daniel S. Sundheim 10 percent owner C/O D1 CAPITAL PARTNERS L.P., 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
Erica J. Rogers director C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089

Sight Sciences (Sight Sciences) Headlines

From GuruFocus

Sight Sciences Announces Addition of New Director Catherine Mazzacco

By sperokesalga sperokesalga 06-09-2023